NasdaqGM:MNKDBiotechs
MannKind (MNKD) Is Up 10.0% After FDA Drops Afrezza Lung Cancer Trial Requirement – What’s Changed
In late May 2026, MannKind Corporation disclosed that the FDA has released it from a large, long-planned postmarketing lung cancer risk trial for Afrezza, leaving only a pediatric efficacy and safety requirement, while multiple new Afrezza and FUROSCIX data sets were presented at the American Diabetes Association’s 2026 Scientific Sessions.
This shift meaningfully reduces Afrezza’s regulatory burden just as MannKind is pushing into pediatric use, including an ongoing INHALE-1st study in...